Abstracts baseline costs, while switchers to an SNRI had a $254 reduction. However, switchers to a generic SSRI had a $99 increase in medical costs. Controlling for baseline characteristics, escitalopram switchers had the highest total health care cost reduction of the three groups, with $383 (P 0.016) in savings relative to SNRI switchers and $172 (P 0.276) in savings relative to switchers to a generic SSRI. CONCLUSIONS: MDD patients requiring second line therapy who switched to escitalopram had signifi cantly lower urgent care utilization than patients switching to an SNRI or another generic SSRI. Using escitalopram as second-line therapy appears to be a cost saving strategy compared to using SNRIs or generic SSRIs.
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COST-EFFECTIVENESS OF OLANZAPINE LONG-ACTING INJECTION IN THE TREATMENT OF NON-ADHERENCE PATIENTS WITH SCHIZOPHRENIA IN THE UNITED STATES
Lilly USA, LLC, Indianapolis, IN, USA OBJECTIVES: This study examines, from a U.S. health care perspective, the costeffectiveness of olanzapine long-acting injection (OLAI) compared to risperidone long-acting injection, haloperidol decanoate, and oral olanzapine in the treatment of schizophrenia patients who are nonadherent with oral antipsychotics. METHODS: A 1-year microsimulation economic decision model was developed to simulate the dynamic usual care of schizophrenia patients who may switch, continue, discontinue, and restart medications. The model captures clinical and cost parameters including adherence levels, relapse with and without hospitalization, quality adjusted life years (QALYs), treatment discontinuation by reason, treatment-emergent adverse events, suicide, health care resource utilization, and direct medical care costs. Published medical literature, unpublished data, and a clinical expert panel were used to develop baseline model assumptions. Key model outcomes included annual total direct cost per treatment, cost per stable patient, and incremental cost-effectiveness values per 1 QALY gained. RESULTS: OLAI was found to have an incremental cost of $60,273/ QALY over haloperidol decanoate. OLAI dominated all other comparators by producing more QALYs and fewer inpatient relapses (dominant over RLAI) or by producing more QALYs and fewer inpatient relapses with a lower incremental cost-effectiveness ratio (extended dominance over oral olanzapine). The base case and multiple sensitivity analyses found OLAI to be a cost-effective option in terms of incremental cost/ QALY gained. Results were most sensitive to change in the cost of relapse. CONCLU-SIONS: OLAI is projected in this microsimulation model to be a cost-effective treatment option for a costly, complex, and challenging group of patients -nonadherent schizophrenia patients -by yielding more QALYs and fewer inpatient relapses than each comparator and providing a cost-effective option in terms of incremental cost per QALY gained.
PMH22 ECONOMIC EVALUATION OF AGOMELATINE FOR MAJOR DEPRESSIVE DISORDER IN SWEDEN
Innovus, Stockholm, Stockholm, Sweden, 2 i3 Innovus, Stockholm, Sweden OBJECTIVES: Agomelatine is the fi rst melatonergic antidepressant approved by the European Medicine Agency for the treatment of major depressive disorder (MDD) in adults. The objective of our study was to perform a cost-effectiveness analysis for agomelatine based on clinical trials against placebo and venlafaxine from a Swedish societal perspective. METHODS: We developed a Markov model with health states for well, depressive episode, remission and death. The model also incorporated sleep disorders, discontinuation rates, discontinuation symptoms and adverse drug reactions (incl. constipation, diarrhoea, dyspepsia, headache, nausea, somnolence and sexual dysfunction). The time horizon was set to two years. Relapse and discontinuation rates were estimated using Weibull regressions, while remission rates were estimated directly. Costs and utilities for different health states were taken from a Swedish observational study. Frequencies of adverse events, sleep disorders and discontinuation symptoms were taken from three relevant trials, while costs and disutilities were estimated from the literature. Costs (reported in EUR 2008) and effects were discounted at 3% per year. RESULTS: In the base case, agomelatine is cost-saving and more effective than venlafaxine and placebo. One-way sensitivity analyses showed that the results were robust to most parameter changes. At a willingness-to-pay threshold of €50,000 per quality-adjusted life year gained, agomelatine was cost-effective compared to venlafaxine in 96% of the cases in the probabilistic sensitivity analysis. CONCLU-SIONS: Based on data from clinical trials and the literature, our results indicate that agomelatine is cost-saving and more effective than venlafaxine in treating MDD in Sweden. These results are robust, confi rmed by sensitivity analysis.
PMH23 PREGABALIN FOR THE TREATMENT OF GENERALIZED ANXIETY DISORDERS (GAD) -A COST-EFFECTIVENESS CASE STUDY OF MEXICO
Arreola-Ornelas H 1 , Rosado-Buzzo AA 2 , García-Mollinedo MDL 2 , Dorantes-Aguilar J 1 , Mould-Quevedo J Q J 3 , Davila-Loaiza G 3 1 Fundación Mexicana para la Salud, Mexico City, Mexico, 2 Links & Links S.A. de C. V, Mexico City, Mexico, 3 Pfi zer Mexico, Mexico City, Mexico OBJECTIVES: Of the various subtypes of anxiety disorders, generalized anxiety disorder (GAD) is the most frequent, lifetime prevalence 6.2%, and is connected with relevant economic and societal consequences. The aim of this study was to assess the cost-effectiveness of pregabalin in the treatment of GAD from an institutional perspective. METHODS: We developed a three-state Markov model to simulate health and economic outcomes during a time horizon of one-year (12-week cycles). The model includes several stages related to disability (complete response, partial response and relapse). Effectiveness was assumed as the percentage of patients with complete response at the end of the follow-up period using the Hamilton Anxiety Rating Scale (HAM-A) (50% reduction related to baseline score) and a Clinical Global Impression of Improvement (CGI-I) score of 1 or 2. Transition probabilities were obtained from a meta-analysis involving international published trials. Comparators used in the assessment were paroxetine (10-40 mg/day); venlafaxine (75-225 mg/day) and pregabalin (300-450 mg/day). Resource use and costs were obtained from 4,000 randomized hospital records from the Social Security Mexican Institute (IMSS). Costs included outpatient and inpatient services, drug, procedures, etc. The model was calibrated. Probabilistic sensitivity analyses were performed employing bootstrapping techniques and acceptability curves were constructed. RESULTS: The highest percentage of patients with complete response to the HAM-A scale during the follow-up period was obtained by pregabalin (39.8%; CI95% 38.5%-41.1%), followed by venlafaxine (22.6%; CI95% 21.9%-23.4%) and paroxetine (16.5%; CI95% 16.0%-17.0%). Regarding the CGI-I the highest percentage for complete response was for pregabalin (35.3%; CI95% 34.2%-36.5%); followed by venlafaxine (28.8%; CI95% 27.8%-29.7%) and paroxetine (16.6%; CI95% 16.1%-17.2%). The annual expected mean costs per patient were US$1,893.1 (US$1,830.7-US$1955.4), US$2001 .2(US$1935 .3-US$2067 and US$955.1(US$923.6-US$986.5). The ICER for pregabalin vs. paroxetine (baseline) was US$4019.7 (US$3887.3-US$4153.7) for HAM-A and US$5017.9(US$4852.6-US$5183.2) for CGI-I. Second-order Monte Carlo sensitivity analyses showed that pregabalin was a cost-effective therapy (p 0.05). CONCLUSIONS: Pregabalin showed to be a costeffective therapy due to its higher effi cacy response in the management of GAD.
PMH24 PHARMACOECONOMIC EVALUATION OF PHARMACOLOGICAL INTERVENTIONS IN GENERALIZED ANXIETY DISORDERS (GAD) IN MEXICO
Mould-Quevedo J Q J 1 , Contreras-Hernandez I 2 , Davila-Loaiza G 1 1 Pfi zer Mexico, Mexico City, Mexico, 2 Social Security Mexican Institute, Mexico City, Mexico OBJECTIVES: Recognition and understanding of generalized anxiety disorder (GAD) have expanded in recent years. GAD is associated with high use of health care resources, predominantly primary care, and its economic burden on society is considerable. The objective of this study was to assess the cost-effectiveness of current treatments for GAD from the payer's perspective. METHODS: We developed a microsimulation model to estimate costs and effectiveness during a time horizon of 12 weeks. Effectiveness was assumed as the percentage of patients with complete response at the end of the follow-up period using the Hamilton Anxiety Rating Scale (HAM-A) -over 50% reduction related to baseline score-and Quality Adjusted Life Years
